EPS
EPS, established in 1991, is a leading Japanese CRO with 1,800 employees helping global customers rediscover and appreciate true value in the Asian markets, including Japan, China, South Korea, Hong Kong (China), Singapore and Taiwan (China). EPS remains the clients' first choice in monitoring, data management and biostatistics with dynamic assignment algorithms and in the therapeutic area of Oncology due to its distinguished expertise and achievements through 1,300 protocols of Phase I-IV, post-marketing surveillance and doctor-led studies, incorporating e-Clinical Technology and in combination with related services including pre-clinical testing, Medical Writing, GCP-Auditing, SMO and CSO for a seamless integrated solution.
Locations
- APAC
Therapeutic Areas
- Bone / Osteoporosis
- Cardiovascular
- CNS
- Dental and Oral Health
- Dermatology
- Diabetes
- Endocrinology
- Gastroenterology
- Genetic Diseases
- Hematology
- Hepatology
- Immunology
- Infectious Diseases
- Inflammation
- Internal Diseases
- Metabolic Diseases
- Musculoskeletal
- Nephrology
- Neurology
- Nutrition and Health
- Obstetrics / Gynecology
- Oncology
- Ophthalmology
- Orthopedics
- Otolaryngology/ENT (Ear/Nose/Throat)
- Pediatrics / Neonatology
- Pharmacology / Toxicology
- Podiatry
- Psychiatry
- Pulmonary
- Respiratory
- Rheumatology
- Sensory Organs
- Sleep
- Thrombosis
- Urology
- Vaccines